HAE - Haemonetics Corporation
| Previous Close | 115.89 |
| Open | 116.00 |
| Bid | 116.77 x 900 |
| Ask | 116.82 x 1000 |
| Day's Range | 115.55 - 117.59 |
| 52 Week Range | 80.24 - 119.85 |
| Volume | 293,583 |
| Avg. Volume | 535,107 |
| Market Cap | 5.979B |
| Beta (3Y Monthly) | 0.51 |
| PE Ratio (TTM) | 112.14 |
| EPS (TTM) | 1.04 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 112.57 |
- Zacks•yesterday
Here's Why You Should Retain Allscripts (MDRX) Stock Now
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
- Insider Monkey•5 days ago
Hedge Funds Have Never Been More Bullish On Haemonetics Corporation (HAE)
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
- Zacks•5 days ago
Here's Why You Should Invest in Cooper Companies Stock Now
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
- Zacks•6 days ago
Here's Why You Should Hold on to Stryker (SYK) Stock Now
Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.
- Zacks•6 days ago
Haemonetics on a High Owing to Firm Plasma Arm, Global Growth
Continued traction in new business wins and expansion of geographies are lifting Haemonetics' (HAE) performance of late.
- Zacks•7 days ago
Haemonetics' Plant Sell-Off to CLS Plasma to be Strategic Fit
This impending divestment remains integral to Haemonetics' (HAE) asset optimization strategy that aims at improving its operational performance and focusing on core competencies.
- Zacks•7 days ago
AMN Healthcare (AMN) Closes Advanced Medical Acquisition
AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.
- Zacks•7 days ago
Agios (AGIO) Catches Eye: Stock Jumps 5.4%
Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Simply Wall St.•7 days ago
Is Haemonetics Corporation (NYSE:HAE) A Financially Sound Company?
Stocks with market capitalization between $2B and $10B, such as Haemonetics Corporation (NYSE:HAE) with a size of...
- Zacks•8 days ago
Here's Why You Should Hold on to PRA Health (PRAH) Stock Now
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
- Zacks•11 days ago
Will Haemonetics Surge Higher?
As of late, it has definitely been a great time to be an investor Haemonetics.
- Zacks•12 days ago
Medical Products Industry Outlook: Growth Prospects Radiant
Medical Products Industry Outlook: Growth Prospects Radiant
- Zacks•13 days ago
Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
- Zacks•14 days ago
Ecolab Unveils Innovative Tested Tool to Improve Food Safety
Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.
- Zacks•14 days ago
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
- Zacks•15 days ago
Here's Why You Should Retain HMS Holdings (HMSY) Stock
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.
- Markit•15 days ago
See what the IHS Markit Score report has to say about Haemonetics Corp.
Haemonetics Corp NYSE:HAEView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HAE with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $194 million over the last one-month into ETFs that hold HAE are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•18 days ago
Here's Why You Should Retain NextGen Healthcare (NXGN) Stock
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
- Zacks•19 days ago
Why Is Haemonetics (HAE) Up 7% Since Last Earnings Report?
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•19 days ago
Here's Why You Should Invest in DexCom (DXCM) Stock Now
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
- Zacks•22 days ago
Here's Why You Should Hold on to Medidata (MDSO) Stock Now
Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.
- Zacks•22 days ago
3 Reasons Growth Investors Will Love Haemonetics (HAE)
Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- Simply Wall St.•27 days ago
A Note On Haemonetics Corporation's (NYSE:HAE) ROE and Debt To Equity
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Zacks•28 days ago
Here's Why You Should Bet on Merit Medical (MMSI) Stock Now
Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.
